Pharming Group (NASDAQ:PHAR) N.V. is a biotechnology company that specializes in the development and commercialization of innovative protein replacement therapies for the treatment of rare diseases. The company’s core expertise lies in leveraging recombinant human proteins produced in transgenic production platforms, a proprietary technology that enables the large-scale manufacturing of complex therapeutic proteins. Pharming’s lead product is RUCONEST, a highly purified C1 esterase inhibitor used to treat acute attacks of hereditary angioedema (HAE), a rare genetic condition characterized by recurrent episodes of severe swelling.
RUCONEST is the only recombinant C1 inhibitor derived from the milk of genetically engineered rabbits, providing a consistent and animal-pathogen–free source of protein. Since receiving marketing approvals in Europe, the United States and several other jurisdictions, RUCONEST has become an established treatment option for HAE patients, with commercial operations managed through a combination of direct sales forces and partnerships with specialty pharmaceutical distributors. The company continues to pursue label expansions for RUCONEST, including prophylactic indications and uses in other complement-mediated disorders.
Beyond its flagship product, Pharming maintains a diversified pipeline of clinical-stage assets targeting additional rare and orphan indications. Research collaborations and licensing agreements with academic institutions and pharmaceutical partners support the advancement of new molecular entities, including small molecules and biologics aimed at neurological, hematological and immunological conditions. Pharming also explores strategic business development opportunities to extend its geographic footprint, with active markets in Europe, North America and Latin America.
Founded in 1988 and headquartered in Leiden, the Netherlands, Pharming Group completed a secondary listing on the NASDAQ Global Market in 2019 under the ticker PHAR, enhancing its access to U.S. capital markets. Under the leadership of Chief Executive Officer Sijmen de Vries and a multidisciplinary management team, the company remains focused on delivering breakthrough therapies for underserved patient populations while pursuing sustainable growth through innovation and strategic collaborations.
